{
    "clinical_study": {
        "@rank": "146125", 
        "acronym": "TAURUS", 
        "arm_group": [
            {
                "arm_group_label": "Tivozanib Hydrochloride", 
                "arm_group_type": "Experimental", 
                "description": "1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks, followed by 50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks."
            }, 
            {
                "arm_group_label": "Sunitinib", 
                "arm_group_type": "Active Comparator", 
                "description": "50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks, followed by 1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride\n      and sunitinib in subjects with metastatic RCC who have received no prior systemic therapy\n      for Renal Cell Carcinoma (RCC).  Approximately 160 subjects will be stratified for ECOG\n      score (0 vs 1) and histology (clear cell vs non-clear cell) and then will be randomized 1:1\n      to 1 of 2 treatment arms.   The study consists of two 12-week treatment periods with a\n      1-week washout in between.  Subjects will receive double-blind (over-encapsulated) tivozanib\n      hydrochloride and sunitinib sequentially.  The study is designed to compare subject\n      treatment preference, as well as overall safety and tolerability, frequency of dose\n      modifications and kidney-specific health outcomes/QoL."
        }, 
        "brief_title": "A Subject Treatment Preference Study of Tivozanib Hydrochloride Versus Sunitinib in Subjects With Metastatic Renal Cell Carcinoma", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Metastatic Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Unresectable mRCC\n\n          -  Histologically or cytologically confirmed RCC of any histology\n\n          -  Subjects with or without prior nephrectomy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n        Exclusion Criteria:\n\n          -  Any prior systemic therapy for treatment of mRCC (including investigational or\n             licensed drugs that target VEGF or VEGF receptors/pathway, or are mammalian target of\n             rapamycin [mTOR] inhibitors)\n\n          -  Central nervous system malignancies or metastases\n\n          -  Significant hematologic, gastrointestinal, thromboembolic, vascular, bleeding, or\n             coagulation disorders\n\n          -  Significant serum chemistry or urinalysis abnormalities\n\n          -  Significant cardiovascular disease, including symptomatic left ventricular ejection\n             fraction or baseline LVEF of \u2264 institutional lower limit of normal, uncontrolled\n             hypertension, myocardial infarction or severe angina within 6 months prior to\n             administration of first dose of study drug, history of class III or IV congestive\n             heart failure, or history of serious ventricular arrhythmia, cardiac arrhythmias, or\n             coronary or peripheral bypass graft within 6 months of screening\n\n          -  Corrected QT interval (QTc) of >480 msec using Bazett's formula\n\n          -  Currently active second primary malignancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01673386", 
            "org_study_id": "AV-951-12-205"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tivozanib Hydrochloride", 
                "intervention_name": "Tivozanib Hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sunitinib", 
                "intervention_name": "Sunitinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sunitinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Tivozanib hydrochloride", 
            "renal cell carcinoma", 
            "subject preference", 
            "quality of life"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "link": {
            "url": "http://www.aveooncology.com/"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albany", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shreveport", 
                        "country": "United States", 
                        "state": "Louisiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Worcester", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlestown", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Myrtle Beach", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antwerp", 
                        "country": "Belgium"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aviano", 
                        "country": "Italy"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "state": "Scotland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Swansea", 
                        "country": "United Kingdom", 
                        "state": "Wales"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "France", 
                "Germany", 
                "Italy", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Randomized, Double-Blind, Crossover, Controlled, Multi-Center Subject Preference Study of Tivozanib Hydrochloride Versus Sunitinib in the Treatment of Subjects With Metastatic Renal Cell Carcinoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Belgium: Agence F\u00e9d\u00e9rale des M\u00e9dicaments et des Produits de Sant\u00e9 (AFMPS/FAGG)", 
                "France: Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS)", 
                "Germany: Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM)", 
                "Italy: Ministry of Health, Agenzia Italiana del Farmaco (AIFA)", 
                "Spain: \u00c1rea de Ensayos Cl\u00ednicos, Subdirecci\u00f3n General de Medicamentos de Uso Humano, Unidad de Registro y Tasas de la AEMPS", 
                "UK: Medicines & Healthcare products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Proportion of subjects who prefer tivozanib hydrochloride or sunitinib", 
            "safety_issue": "No", 
            "time_frame": "Up to 25 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01673386"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects with AEs and SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 25 weeks"
            }, 
            {
                "measure": "Number of subjects with dose reductions", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 25 weeks"
            }, 
            {
                "measure": "Number of subjects with dose interruptions", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 25 weeks"
            }, 
            {
                "measure": "Number of subjects with Grade 3/4 hematology abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 25 weeks"
            }, 
            {
                "measure": "Number of subjects with Grade 3/4 chemistry abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 25 weeks"
            }, 
            {
                "measure": "Number of subjects with Grade 3/4 coagulation abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 25 weeks"
            }, 
            {
                "measure": "Number of subjects with Grade 3/4 urinalysis abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 25 weeks"
            }, 
            {
                "measure": "Number of subjects with Grade 3/4 thyroid function abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 25 weeks"
            }, 
            {
                "measure": "Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment"
            }, 
            {
                "measure": "Change from baseline in FACT Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment"
            }, 
            {
                "measure": "Change from baseline in Functional Assessment of Cancer Therapy-Diarrhea (FACT-D)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment"
            }, 
            {
                "measure": "Change from baseline in Euro Quality of Life - 5 Dimensions (EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment"
            }
        ], 
        "source": "AVEO Pharmaceuticals, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AVEO Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}